Beiersdorf

Inline skates for a limping Elephant?

22/02/21 -"We have added the higher CARE expenses to our model, which will be partly cushioned by higher profitability. This negatively effects primarily our EPS in the estimate years, whereas our DCF model is ..."

PDF page sample
Pages
55
Language
English
Published on
22/02/21
Download
You may also be interested by these reports :
15/09/26
Puig has agreed to acquire the remaining 50% stake in ISDIN for €1.2bn, taking full ownership of the dermocosmetics brand. The group will pay €900m ...
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
08/09/26
Bic’s 2030 strategy is credible and modestly positive for earnings and cash flow, with c.3% organic growth and >15.5% EBIT margin targets above the ...
08/09/26
BIC’s new 2030 strategy looks positive for earnings and cash generation, with growth, margin and capex targets ahead of the current consensus. The ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO